Clinical companies

Syncona’s clinical companies have screened and enrolled the first patient into a clinical trial and are scaling towards late-stage development.

Syncona’s clinical portfolio comprises companies with the potential to treat patients across a range of conditions.

Key facts

Unless stated all financials at 31 December 2025

£296.3m

Value of clinical portfolio

Number of clinical trials

Portfolio Company Board seats

Our clinical stage portfolio companies

20.06.24

Introducing iOnctura

24.06.21

Anaveon doses first patient

11.02.21

Introduction from Quell Therapeutics, CEO, Iain McGill

11.02.21

Quell: the science and the unmet medical need for patients

11.02.21

Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion

02.12.20

Introducing Resolution Therapeutics

19.11.20

Introduction to Purespring

15.10.19

Quell Therapeutics and an emerging area of cell therapy

15.10.19

Founding Quell Therapeutics

View all insights and articles

Best ideas Pre-clinical Clinical Late Clinical BLA